The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Overview

Journal Trends Immunol

Specialty Allergy & Immunology

Date 2016 Feb 10

PMID 26858199

Citations 1030

Authors

Vinit Kumar

Sima Patel

Evgenii Tcyganov

Dmitry I Gabrilovich

Affiliations

Soon will be listed here.

Abstract

Myeloid-derived suppressor cells (MDSC) are one of the major components of the tumor microenvironment. The main feature of these cells is their potent immune suppressive activity. MDSC are generated in the bone marrow and, in tumor-bearing hosts, migrate to peripheral lymphoid organs and the tumor to contribute to the formation of the tumor microenvironment. Recent findings have revealed differences in the function and fate of MDSC in the tumor and peripheral lymphoid organs. We review these findings here and, in this context, we discuss the current understanding as to the nature of these differences, the underlying mechanisms, and their potential impact on the regulation of tumor progression.

Citing Articles

The role of tumor-associated macrophages in lung cancer.

Zhu R, Huang J, Qian F Front Immunol. 2025; 16:1556209.

PMID: 40079009 PMC: 11897577. DOI: 10.3389/fimmu.2025.1556209.

Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma.

Ren S, Zhang Y, Wang X, Su J, Wang X, Yuan Z Front Immunol. 2025; 16:1526967.

PMID: 40070843 PMC: 11893557. DOI: 10.3389/fimmu.2025.1526967.

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.

Harnessing myeloid cells in cancer.

Park S, Pylaeva E, Bhuria V, Gambardella A, Schiavoni G, Mougiakakos D Mol Cancer. 2025; 24(1):69.

PMID: 40050933 PMC: 11887392. DOI: 10.1186/s12943-025-02249-2.

Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.

Yang Z, Ha B, Wu Q, Ren F, Yin Z, Zhang H Front Immunol. 2025; 16:1544532.

PMID: 40046061 PMC: 11880241. DOI: 10.3389/fimmu.2025.1544532.

References

Pan P, Ma G, Weber K, Ozao-Choy J, Wang G, Yin B . Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2009; 70(1):99-108. PMC: 2805053. DOI: 10.1158/0008-5472.CAN-09-1882. View

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L . Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007; 13(7):828-35. PMC: 2135607. DOI: 10.1038/nm1609. View

Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender Z . Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother. 2013; 62(11):1745-56. PMC: 11028422. DOI: 10.1007/s00262-013-1476-9. View

Pearce E, Everts B . Dendritic cell metabolism. Nat Rev Immunol. 2014; 15(1):18-29. PMC: 4495583. DOI: 10.1038/nri3771. View

Huh S, Liang S, Sharma A, Dong C, Robertson G . Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2010; 70(14):6071-82. PMC: 2905495. DOI: 10.1158/0008-5472.CAN-09-4442. View

Kowalczuk O, Burzykowski T, Niklinska W, Kozlowski M, Chyczewski L, Niklinski J . CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumour Biol. 2014; 35(5):4619-28. PMC: 4009141. DOI: 10.1007/s13277-014-1605-x. View

Biswas S, Mantovani A . Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010; 11(10):889-96. DOI: 10.1038/ni.1937. View

Raber P, Thevenot P, Sierra R, Wyczechowska D, Halle D, Ramirez M . Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer. 2013; 134(12):2853-64. PMC: 3980009. DOI: 10.1002/ijc.28622. View

Haverkamp J, Smith A, Weinlich R, Dillon C, Qualls J, Neale G . Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014; 41(6):947-59. PMC: 4272664. DOI: 10.1016/j.immuni.2014.10.020. View

10.

Liu C, Wang Y, Wang C, Feng P, Ko H, Liu Y . Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2009; 136(1):35-45. DOI: 10.1007/s00432-009-0634-0. View

11.

Yona S, Kim K, Wolf Y, Mildner A, Varol D, Breker M . Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013; 38(1):79-91. PMC: 3908543. DOI: 10.1016/j.immuni.2012.12.001. View

12.

Gijsbers K, Gouwy M, Struyf S, Wuyts A, Proost P, Opdenakker G . GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Exp Cell Res. 2005; 303(2):331-42. DOI: 10.1016/j.yexcr.2004.09.027. View

13.

Marvel D, Gabrilovich D . Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125(9):3356-64. PMC: 4588239. DOI: 10.1172/JCI80005. View

14.

Nagaraj S, Schrum A, Cho H, Celis E, Gabrilovich D . Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010; 184(6):3106-16. PMC: 2832724. DOI: 10.4049/jimmunol.0902661. View

15.

Biswas S, Allavena P, Mantovani A . Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013; 35(5):585-600. DOI: 10.1007/s00281-013-0367-7. View

16.

Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M . The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002; 62(4):1093-102. View

17.

Inamoto S, Itatani Y, Yamamoto T, Minamiguchi S, Hirai H, Iwamoto M . Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15-CCR1 Chemokine Axis. Clin Cancer Res. 2015; 22(2):492-501. DOI: 10.1158/1078-0432.CCR-15-0726. View

18.

Cubillos-Ruiz J, Silberman P, Rutkowski M, Chopra S, Perales-Puchalt A, Song M . ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell. 2015; 161(7):1527-38. PMC: 4580135. DOI: 10.1016/j.cell.2015.05.025. View

19.

Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V . Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014; 1319:47-65. DOI: 10.1111/nyas.12469. View

20.

Yu J, Du W, Yan F, Wang Y, Li H, Cao S . Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013; 190(7):3783-97. DOI: 10.4049/jimmunol.1201449. View